Boehringer Ingelheim Enters Clinical Collaboration with Amgen to Study BI 1701963, a SOS1::pan-KRAS Inhibitor, in Combination with LUMAKRAS™ (sotorasib), a KRASG12C Inhibitor
16.9.2021 15:00:00 EEST | Business Wire | Press release
Boehringer Ingelheim today announced a clinical phase I collaboration with Amgen to evaluate the combination of BI 1701963, the first and most advanced SOS1::pan-KRAS inhibitor exhibiting activity against a broad spectrum of KRAS alleles, and LUMAKRAS™ (sotorasib), the first US Food and Drug Administration (FDA) approved KRASG12C inhibitor for adult patients with locally advanced or metastatic non-small cell lung cancer. The trial will investigate potential synergistic effects of this combination, possibly improving therapeutic outcomes beyond those of KRASG12C inhibitor therapy alone, specifically for people living with lung and colorectal cancers.
Preclinical data suggest that the combination of a KRASG12C inhibitor with a SOS1::pan-KRAS inhibitor may result in increased anti-tumor activity in KRAS G12C-driven cancers based on the complementary mechanisms of these targeted oncology agents.1 2 By shifting the equilibrium from active KRAS towards the inactive form, SOS1::pan-KRAS inhibitors have the potential to sensitize KRAS G12C-mutant tumors to covalent KRASG12C inhibitors that bind to inactive KRAS. In addition, SOS1 inhibitors block feedback reactivation which occurs upon pathway inhibition.
“We are excited to partner with Amgen, who have pioneered KRAS G12C inhibition, and to further expand our program to make a difference for people living with KRAS-driven cancers,” said Francesco Di Marco, Ph.D., Corporate Senior Vice President, Global Therapy Area Head Oncology at Boehringer Ingelheim. “Boehringer Ingelheim follows an ‘all-in’ research approach to taking cancer on, including the first and most advanced SOS1::pan-KRAS inhibitor which we investigate in several combinations and cancer types to realize even more opportunities to deliver potential therapeutic benefits to cancer patients.”
Under the terms of the non-exclusive collaboration, Amgen will be the sponsor of the trial and Boehringer Ingelheim and Amgen will jointly share the costs of and oversee clinical development for the combined therapy.
About BI 1701963
BI 1701963 is an investigational, orally available small molecule, that binds to the catalytic domain of SOS1 preventing the interaction with inactive KRAS. This reduces the formation of active KRAS and in consequence inhibits MAPK pathway signaling in KRAS-dependent cancers. SOS1 inhibition also simultaneously blocks feedback driven reactivation of the MAPK pathway. The selective inhibition of SOS1 is a therapeutic concept that could allow KRAS blockade irrespective of KRAS mutation type (pan-KRAS approach). SOS1::KRAS inhibitors exhibit activity on a broad spectrum of KRAS alleles, including all major G12D/V/C and G13D oncoproteins, as published by Hofmann MH, et al. in Cancer Discovery, a journal of the American Association of Cancer Research (AACR). BI 1701963 is currently being evaluated in phase I clinical trials in patients with advanced KRAS-mutated cancers to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties, and preliminary efficacy of BI 1701963 alone and in combination with MEK inhibitors, KRASG12C inhibitors or irinotecan.
Boehringer Ingelheim’s Intended Audiences Notice
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.
Please click on the following link for ‘Notes to Editors’:
http://www.boehringer-ingelheim.com/press-release/clinical-collaboration-amgen
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005436/en/
Contact information
Media Contacts:
Boehringer Ingelheim
Sarah Soetbeer
Junior Product Communications Manager
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-183874
press@boehringer-ingelheim.com
Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
press@boehringer-ingelheim.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Infobip Expands Relationship With Anthropic With Verified Claude Connector for Global Messaging17.11.2026 11:00:00 EET | Press release
Global AI-first cloud communications platform Infobip has expanded its collaboration with Anthropic with the launch of the Infobip Message connector in the Claude Marketplace. The Anthropic-verified connector enables developers, enterprises and builders using Claude to add global messaging capabilities to AI agents without building separate integrations for individual communication channels. The integration connects Claude with Infobip’s global communications infrastructure, enabling AI agents to send messages across SMS, RCS, MMS and Viber through a single connector. Using Infobip’s send and check status tools, agents can trigger outbound messages and track their delivery status, allowing them to incorporate real-world communication into automated workflows. For businesses building agentic AI applications, the connector can support use cases such as order confirmations, delivery updates and appointment reminders. Instead of developing and maintaining individual messaging integrations,
Luminor Partners With Plumery to Accelerate Delivery of Digital Banking Solutions17.11.2026 10:55:00 EET | Press release
Luminor has partnered with financial technology company Plumery, using its headless digital platform to accelerate the delivery of selected digital banking solutions across Estonia, Latvia and Lithuania. Plumery was selected because its technology and approach align well with Luminor’s strategy. The cooperation forms part of Luminor’s broader work to modernise its technology, simplify its products and strengthen its digital channels. Under the partnership, Luminor uses Plumery’s headless, API-first architecture to design and deliver digital banking experiences in combination with the bank’s own applications, customer journeys and integrations. This allows Luminor to develop and introduce new functionality more efficiently, while retaining control over how its digital services are designed and integrated. Luminor Bloom, hosted on Luminor’s new cloud-based banking platform, is the first solution delivered through the partnership. Plumery provides the digital banking interface used for Lu
Oasis Networks Selects PacketLight for Burstable Wavelength Services17.11.2026 10:35:00 EET | Press release
PacketLight Networks, a provider of DWDM and OTN optical transport solutions, today announced that Oasis Networks has selected its 800G transport and OLS optical amplification platforms to support the development of burstable wavelength services in Portugal. PacketLight’s open transport architecture supports Oasis’ plans to allocate optical capacity through software as customer requirements change. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117351242/en/ PacketLight’s 800G DWDM transport and OLS optical amplification support Oasis Networks’ Lisbon–Sines connection and the development of burstable wavelength services. The connection between Lisbon and Sines is now in place, with the Sines endpoint at Start Campus. A proof of concept on Oasis’ operational network demonstrated software-controlled optical path establishment and reconfiguration. PacketLight has also completed the design for future site interconnects around
Abu Dhabi International Boat Show Opens This Week With World Premieres and Record Participation17.11.2026 10:27:00 EET | Press release
Held under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region, the Abu Dhabi International Boat Show (ADIBS) returns from 19 to 22 November 2026 at ADNEC Marina Hall for its eighth and largest edition yet, bringing together 1,210 exhibitors and brands from 57 countries, a 13% increase on 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261116669938/en/ ADNEC Marina Hall - ADNEC Group, Abu Dhabi – United Arab Emirates (Photo: AETOSWire) Organised by ADNEC Group under the theme “Life on and Beyond the Water”, the show spans more than 96,000 square metres and will feature 168 boats on display in the marina. Additionally, luxury yachts, houseboats, leisure boats and marine sports equipment will be launched for the first time in the region. “This year’s edition is set to be the largest in the Show’s history, with strong growth across key performance indicators reflectin
Tractivity Joins European Technology Group to Strengthen Stakeholder Engagement Across Europe17.11.2026 10:00:00 EET | Press release
European Technology Group (ETG), a long-term oriented European GovTech platform, welcomes Tractivity, a leading stakeholder relationship management software provider in Europe, to its family. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117911743/en/ Tractivity Joins European Technology Group to Strengthen Stakeholder Engagement Across Europe The transaction marks the next stage of Tractivity’s development after sustained growth. The company serves more than 100 organisations across energy, utilities, healthcare, central and local government, regulators and transport in Europe. As part of ETG, Tractivity will build on its established brand, long-standing customer trust and clear product focus. ETG adds resources and know-how to accelerate product development and invest in AI capabilities that make stakeholder engagement more efficient. ETG’s European network will support Tractivity’s expansion across Europe and among en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
